Lilly ESG Updates: Creating Sustainable Impact for All Stakeholders

At Lilly, we create medicines that make life better for people around the world. But we understand that delivering lifesaving medicines is just the start of the conversation. 

Lilly has a proud history of sustainability, but today, more than ever, we believe our ESG (environmental, social and governance) performance is central to our impact on society — and our overall success. 

While this focus is not new, we are redoubling our efforts — increasing our investment in sustainability, setting new goals and communicating our progress in new ways to our stakeholders. 

Below, you can see our latest ESG developments. You can find our detailed 2020 ESG report at esg.lilly.com.

Sustainability

• Lilly announces sustainability bond offering. The proceeds of this bond will be allocated to fund several of our environmental and social efforts – including pollution prevention, energy efficiency, renewable energy and wastewater management, as well as global health and supplier diversity. 

• Lilly announces its 2020 ESG Report and hosts a sustainability call with investors to share new ESG goals, investments and progress. Listen to the call; view the slide presentation. 

Access and Affordability

• Lilly again reduces list price of Insulin Lispro Injection. The lower list price is the latest among numerous options that can reduce out-of-pocket costs for Lilly insulin at U.S. retail pharmacies.

• Lilly commits an additional $5 million to the Diabetes Impact Project (DIP-IN), launched in 2018 to drive long-term improvements in diabetes diagnosis, care and overall lifespan in three Indianapolis neighborhoods where residents are predominantly people of color.

Community Engagement

• Lilly announces investment in Sixty8 Capital, an Indianapolis-based Black-owned, venture capital firm supporting Black, Latinx, women and LGBTQ+ startups, as we aim to open the door to missed opportunities for diverse innovators and empower change within our communities.